Registration Opens for SMi's 9th Annual Orphan Drugs & Rare Diseases Conference
SMi Reports: Registration is now open for the Orphan Drugs & Rare Diseases Conference, taking place in London, UK, this October.
By: SMi Group
With this in mind, SMi Group are delighted to announce the 9th Annual Orphan Drugs & Rare Diseases Conference, returning to London, UK on the 15th and 16th October 2019. This year's Conference will bring together solution providers, biotechnology companies, clinical researchers, regulatory professionals and charity leaders to discuss possible ways to accelerate orphan drug development and access to rare disease patients, including the introduction of recent technologies and products to help aid the access of orphan drugs.
For those interested in attending, there is a £400 early bird discount on bookings ending on Friday 31st May 2019. Register online on the event website.
The two-day event will be chaired by Rick Thompson, CEO at Findacure. Dr Rick Thompson joined Findacure in 2015, after completing his PhD in Evolutionary Biology at the University of Cambridge. He began working as Findacure's first Scientific Officer, helping to develop the charity's proof of concept study for the innovative drug repurposing social impact bond. Having been promoted to CEO in May 2017, Rick now oversees the charity's strategy and development, oversees major funding applications, and manages the team, while still maintaining Findacure's scientific projects.
The agenda features over 16 presentations from industry experts, including:
· Katrin Radl, Senior Manager Evidence Generation & Patient Access, Takeda
· Sheela Upadhyaya, HST Associate Director, NICE
· Mike Page, Executive Director Global Regulatory Affairs Portfolio Products, Alexion Pharmaceuticals
· Donatello Crocetta, VP Global Head Rare Immunology Franchise, Takeda
· Martin Garau, Associate Director, Office of Health Economics
· Jayne Spink, CEO, Genetic Alliance UK
Conference attendees will have the opportunity to evaluate the key challenges to advance commercialisation and patient access, through key sessions including:
· Assessment of the collaboration of pharmaceutical companies and investors
· SPOTLIGHT PRESENTATION:
· Overview of current orphan drug regulation
· OPENING ADDRESS: Collaborations in rare disease research and commercialisation
· Charting the path to diagnosis for patients with rare diseases
· CHIESI CASE STUDY: Holuclar
· Early access for orphan drugs
Attendees also have the chance to attend the half day post-conference workshop on 'A deep dive into strategies for accelerating patient access of orphan drugs' led by Solange Corriol-Rohou, Senior Director Regulatory Affairs & Policy Europe, AstraZeneca and Cecile Ollivier, Chief Operating Officer, Aparito.
The Orphan Drugs & Rare Diseases conference invites CEOs, CSOs, Vice Presidents, Directors, Heads, Principals working in: Medical Affairs, Medical Advisory, Clinical Operations, Rare Disease Research, Patient Advocacy, Commercial Officer, Orphan Drug Therapeutics, Healthcare, Regulatory Affairs, Rare Disease Charity Officers, and for those who work or have an interest in orphan drugs and rare diseases.
The brochure with the full agenda and speaker line-up is available to download online at https://www.smi-
For sponsorship enquires, contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or email email@example.com
SMi's 9th Annual Orphan Drugs & Rare Diseases Conference
Conference: 15-16 October 2019
Workshop: 17 October 2019
Holiday Inn Kensington Forum, London, UK
---- END ----
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-